History

Liraglutide was developed by Novo Nordisk in Denmark, with Lotte Bjerre Knudsen credited as a lead inventor; it carried the development code NN2211 in early studies. The molecule attaches a fatty-acid chain to native GLP-1 so it binds albumin and resists breakdown, extending its half-life to roughly 13 hours. The EMA authorized Victoza for type 2 diabetes in 2009, the FDA followed in January 2010, and the higher-dose Saxenda was approved for obesity in December 2014 — the first GLP-1 analogue cleared for weight management.

Liraglutide is one of the better-studied metabolic drugs of the last fifteen years, and the direct predecessor to semaglutide. Its two approved uses rest on large, replicated, double-blind randomized trials with hard endpoints, so the honest job here is to separate what the evidence firmly supports from the investigational and gray-market claims that ride alongside it.

What it is

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: a modified copy of a gut hormone the body releases after eating, sharing about 97% of its sequence with native GLP-1. Two structural changes set it apart from the natural hormone — an arginine-to-lysine swap at position 34, and a C16 fatty-acid (palmitic) chain attached through a glutamic-acid spacer to lysine 26. That fatty-acid tail makes the molecule bind tightly to albumin in the blood (over 98% protein-bound) and cluster with itself, which shields it from the enzyme that normally degrades GLP-1 within minutes. The result is a half-life of roughly 13 hours, allowing once-daily injection.

By activating GLP-1 receptors in the pancreas, gut, and brain, it triggers insulin release when blood sugar is high, suppresses glucagon, slows stomach emptying, and reduces appetite. Because the insulin effect is glucose-dependent, liraglutide on its own carries a low risk of hypoglycemia. It is sold as Victoza (for type 2 diabetes), Saxenda (a higher-dose version for chronic weight management), and as a component of the fixed-dose combination Xultophy with insulin degludec.

The claims

The mainstream, label-backed claims are straightforward: better blood-sugar control in type 2 diabetes, meaningful weight loss, and reduced risk of heart attack and stroke in high-risk diabetic patients. Investigationally, liraglutide has also been tested for fatty liver disease (NASH/MASH), Alzheimer’s disease, and PCOS. Online and gray-market sellers promote it more loosely for cosmetic weight loss and “metabolic optimization,” stripped of the prescription, screening, and monitoring framework that comes with the approved product.

The evidence

The approved uses are backed by large randomized controlled trials, not anecdote.

Blood sugar (LEAD program): Six randomized, double-blind phase-3 trials enrolled over 4,000 adults with type 2 diabetes across 40 countries. Liraglutide lowered HbA1c by up to about 1.5%, generally outperforming comparators such as sitagliptin, glimepiride, and insulin glargine, with modest weight loss and nausea as the dominant side effect.
Heart outcomes (LEADER): This is the strongest evidence. In a randomized, double-blind, placebo-controlled trial of 9,340 adults with type 2 diabetes at high cardiovascular risk, followed for a median of 3.8 years, liraglutide cut the primary composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke (HR 0.87), reduced cardiovascular death (HR 0.78), and reduced all-cause death (HR 0.85). Notably, this trial was co-funded by the NIH alongside Novo Nordisk.
Weight (SCALE): In a 56-week, double-blind pivotal trial of 3,731 adults without diabetes, the 3.0 mg dose plus lifestyle counseling produced mean weight loss of about 8.4 kg versus 2.8 kg on placebo.
Pediatric diabetes (Ellipse): In a placebo-controlled trial in children aged 10 to under 17, liraglutide added to metformin improved HbA1c over 52 weeks, with more gastrointestinal side effects and — notably — no greater weight loss.

The investigational uses are far weaker. The LEAN trial in fatty liver disease was a single small phase-2 study of just 52 patients; it showed promising histological improvement (NASH resolution in 39% versus 9% on placebo) but is only hypothesis-generating. In Alzheimer’s disease, the ELAD phase-2b trial (204 participants, published 2025) failed its primary endpoint — there was no significant effect on brain glucose metabolism (p=0.14). Some exploratory cognitive measures hinted at slowed decline, but those are not confirmatory.

Two honest caveats apply to the whole picture. First, nearly all of the pivotal trials were funded by the manufacturer, Novo Nordisk; LEADER’s independent NIH co-funding is the main exception. Second, there is no long-term hard-outcome trial of the 3.0 mg obesity dose in non-diabetic people, and liraglutide is now recognized as less potent for weight loss than newer agents like semaglutide and tirzepatide. The animal data often cited for beta-cell benefits are also softer than their headlines suggest — one foundational mouse study titled as showing increased beta-cell mass actually reported only a “strong tendency,” not a statistically significant increase. The human RCTs, not the animal work, carry the grade.

Safety and side effects

The most common effects are gastrointestinal and dose-related, usually easing over time: nausea (around 20%), diarrhea, headache, vomiting, decreased appetite, dyspepsia, and constipation.

Liraglutide carries a boxed warning for thyroid C-cell tumors, based on findings in rats and mice; whether this translates to humans is undetermined. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.

Pancreatitis has been a recurring concern. Acute pancreatitis, including severe cases, has been reported after marketing, and the drug should be stopped if it is suspected. However, the early causal-signal worry was not substantiated by regulators: a 2014 joint FDA–EMA assessment concluded the data were inconsistent with a causal link to pancreatitis or pancreatic cancer. A pooled analysis of liraglutide trials reached the same overall conclusion, though it is worth being candid that it found a numerical imbalance — 1.6 versus 0.7 acute pancreatitis cases per 1,000 patient-years — which the authors judged too small to establish causality. A separate claims-based study likewise found no clear elevation in risk.

Other documented label items include gallbladder disease (gallstones and cholecystitis, partly tied to weight loss), low blood sugar when combined with insulin or sulfonylureas, kidney injury (often alongside dehydration from vomiting or diarrhea), increased heart rate, hypersensitivity reactions, and — for Saxenda — monitoring for suicidal ideation. This is not medical advice; the approved product requires a prescription and clinical monitoring.

Legal and regulatory status

Liraglutide is an approved prescription drug, not a supplement or research chemical. The FDA approved Victoza for type 2 diabetes on January 25, 2010, and Saxenda for chronic weight management on December 23, 2014 — the first GLP-1 analogue approved for obesity, later extended to adolescents. The EMA authorized Victoza in 2009 and Saxenda in March 2015.

For athletes: as of the 2026 WADA Prohibited List, GLP-1 receptor agonists are not prohibited. Related drugs semaglutide and tirzepatide sit on WADA’s Monitoring Program, which tracks use without sanctions; liraglutide is not individually named as banned. Claims circulating on some supplement-vendor pages that GLP-1 drugs were moved to full prohibition in January 2026 are contradicted by reputable sources and should not be trusted — always check the official WADA list.

Branded liraglutide is prescription-only in the US and EU. Material sold online as a “research peptide” carries no guarantee of identity, purity, sterility, or accurate dosing, and bypasses the boxed warning, contraindication screening, and pharmacovigilance that govern the approved product.

Bottom line

For its two approved uses — glucose control in type 2 diabetes and chronic weight management — liraglutide is a genuinely effective drug supported by large, replicated trials, with risks that are real but generally manageable under medical supervision. Its cardiovascular benefit in high-risk diabetic patients is among the better-documented findings in the class. The honest qualifications are that most trials were manufacturer-funded, the investigational uses (fatty liver, Alzheimer’s) are preliminary or outright negative, and newer GLP-1 drugs now achieve more weight loss. The grade applies to the approved indications, not the gray-market promises.

Evidence grade: Strong human.

Liraglutide (Victoza / Saxenda): An Evidence Review